Private Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.19M Hold
13,200
0.1% 37
2026
Q1
$1.06M Hold
13,200
0.12% 37
2025
Q4
$1.13M Hold
13,200
0.11% 39
2025
Q3
$1.03M Hold
13,200
0.11% 43
2025
Q2
$1.03M Hold
13,200
0.13% 41
2025
Q1
$957K Hold
13,200
0.11% 40
2024
Q4
$977K Hold
13,200
0.12% 41
2024
Q3
$871K Hold
13,200
0.1% 45
2024
Q2
$1.22M Hold
13,200
0.14% 43
2024
Q1
$1.26M Hold
13,200
0.16% 42
2023
Q4
$1.01M Hold
13,200
0.15% 43
2023
Q3
$841K Sell
13,200
-1,410
-10% -$113K 0.13% 50
2023
Q2
$1.38M Hold
14,610
0.23% 39
2023
Q1
$1.21M Hold
14,610
0.23% 38
2022
Q4
$1.09M Hold
14,610
0.19% 37
2022
Q3
$1.21M Sell
14,610
-19,823
-58% -$1.91M 0.21% 38
2022
Q2
$3.27M Sell
34,433
-11,527
-25% -$1.19M 0.55% 33
2022
Q1
$5.41M Buy
+45,960
New +$5.16M 0.79% 35
2017
Q4
Sell
-9,000
Closed -$328K 108
2017
Q3
$328K Buy
+9,000
New +$343K 0.11% 91

Other funds holding EW

Private Capital Advisors's EW Position: Q2 2026 in Review

Private Capital Advisors held its Edwards Lifesciences (EW) position steady in Q2 2026 at 13,200 shares worth $1.19M. The position accounts for 0.1% of the portfolio, ranked #37.

Private Capital Advisors first reported a position in EW in Q3 2017 and has held it in 19 quarters since. The position peaked at $5.41M in Q1 2022. 372 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Private Capital Advisors held 13,200 shares of Edwards Lifesciences worth $1.19M as of Q2 2026.
  • Private Capital Advisors left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.1% of Private Capital Advisors's portfolio in Q2 2026, its #37 holding.
  • Private Capital Advisors first reported a position in Edwards Lifesciences in Q3 2017 and has held it in 19 quarters since.
  • Private Capital Advisors's Edwards Lifesciences position peaked at $5.41M in Q1 2022.
  • 372 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Private Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.